Tang Capital Management LLC Sells 132,500 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Tang Capital Management LLC decreased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 29.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 317,500 shares of the specialty pharmaceutical company's stock after selling 132,500 shares during the quarter. ANI Pharmaceuticals makes up 1.2% of Tang Capital Management LLC's investment portfolio, making the stock its 22nd largest position. Tang Capital Management LLC owned approximately 1.51% of ANI Pharmaceuticals worth $17,551,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Exchange Traded Concepts LLC grew its stake in shares of ANI Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock valued at $684,000 after buying an additional 310 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of ANI Pharmaceuticals by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock worth $582,000 after buying an additional 364 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock worth $246,000 after acquiring an additional 412 shares during the period. Natixis Advisors LLC lifted its holdings in ANI Pharmaceuticals by 2.3% in the fourth quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock valued at $1,028,000 after acquiring an additional 417 shares during the period. Finally, US Bancorp DE grew its position in shares of ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock valued at $33,000 after acquiring an additional 531 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ANIP has been the topic of several research reports. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price on the stock. StockNews.com cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, April 24th. Guggenheim restated a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $80.13.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP traded down $1.56 on Wednesday, reaching $59.08. 305,823 shares of the company traded hands, compared to its average volume of 300,534. The company's 50 day moving average is $66.83 and its 200-day moving average is $60.80. The stock has a market capitalization of $1.28 billion, a PE ratio of -107.42 and a beta of 0.56. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. During the same quarter last year, the business posted $0.82 EPS. The company's revenue for the quarter was up 43.4% on a year-over-year basis. As a group, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Insider Activity

In other ANI Pharmaceuticals news, insider Christopher Mutz sold 4,000 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the transaction, the insider now directly owns 107,317 shares in the company, valued at approximately $6,487,312.65. This represents a 3.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the completion of the transaction, the senior vice president now owns 89,897 shares of the company's stock, valued at $5,400,112.79. This represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 7,681 shares of company stock worth $468,698. 11.10% of the stock is currently owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.